AIM ImmunoTech (AIM) – Press Releases
-
AI-Media Unveils Enhanced Lexi Tool Kit at NAB 2024
-
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
-
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
-
AIM ImmunoTech Announces Launch of CEO Corner Platform
-
AI-Media's LEXI Tool Kit Expanded with LEXI Recorded - Breakthrough Solution for the Growing VOD Market
-
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
-
Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied
-
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
-
AIM ImmunoTech Provides Update Regarding Annual Meeting
-
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
-
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change
-
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Trip
-
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
-
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
-
Kognitiv Launches AI-Native Kognitiv Ignite: Revolutionary Outcome-Based Customer Engagement Solution
-
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
-
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
AI-Media's AI-Powered LEXI Captioning Tool Kit Raises the Bar
-
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
-
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
-
Kognitiv Announces Sale of Hospitality Technology Business to Valsoft Corp.
-
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
-
Enerpac Tool Group Announces Definitive Agreement to Sell Cortland Industrial to Tufropes
-
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
-
TRADE X Integrates Vehicle Inspection API Through Partnership with PAVE
-
Kognitiv welcomes Jon Ott as Chief Revenue Officer
-
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
-
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
-
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
-
KOGNITIV LAUNCHES POWERFUL NEW AI-DRIVEN KOGNITIV PULSE
-
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
-
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
-
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
-
AIM ImmunoTech Issues Letter to Stockholders
-
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
-
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
-
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
-
Kognitiv Corporation appoints Tim Sullivan as Chief Executive Officer
-
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevent
-
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
-
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
-
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
-
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
-
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the T
-
TRADE X Opens its B2B Trading Platform to Automotive Imports and Exports in Mexico
-
AIM ImmunoTech Announces Corporate Governance Enhancements
-
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
-
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Back to AIM Stock Lookup
